LY2606368 (Prexasertib) is a small-molecule Chk-1 inhibitors invented by Array and being developed by Eli Lilly and Company. Lilly is responsible for all clinical development and commercialization activities. LY2606368 is advancing in Phase 2 clinical trials for cancer. Prexasertib preferentially binds to and inhibits CHK1 and, to a lesser extent, inhibits CHK2. Chk-1 is a protein kinase that regulates the tumor cell's response to DNA damage often caused by treatment with chemotherapy. In response to DNA damage, Chk-1 blocks cell cycle progression in order to allow for repair of damaged DNA, thereby limiting the efficacy of chemotherapeutic agents. Inhibiting Chk-1 in combination with chemotherapy can enhance tumor cell death by preventing these cells from recovering from DNA damage.

LANOPEPDEN is an inhibitor of peptide deformylase, a bacterial enzyme required for protein maturation. It was in development for the treatment of complicated bacterial skin infection and hospitalized community-acquired pneumonia.

Deximafen is antidepressant drug developed by Abbot Laboratories Inc.

Eniclobrate (Sgd 33374), a diphenylmethane derivative, is a lipid-lowering compound. In rodents, eniclobrate lower serum and liver cholesterol levels and reduced the percentage of esterified cholesterol present in the serum but raised liver triglyceride levels. In a clinical trial for the treatment of hyperlipidemia type IIa and type IIb eniclobrate effectively reduced LDL-cholesterol in type IIa, however, there was a remarkable increase in HDL-cholesterol in both types of hyperlipidemia.

Elucaine is local anesthetic and anti-ulcerative agent, acting as a gastric muscarinic acetylcholine receptor antagonist.